Article info

Extended report
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Authors

  1. Correspondence to Dr A Finckh, Division of Rheumatology, Department of Internal Medicine, University Hospital of Geneva, 26 Av Beau-Sejour, 1211 Geneva 14, Switzerland; axel.finckh{at}hcuge.ch
View Full Text

Citation

Finckh A, Ciurea A, Brulhart L, et al
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Publication history

  • Accepted April 20, 2009
  • First published May 4, 2009.
Online issue publication 
January 26, 2010

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.